Objective  To analyze the clinical characteristics of AIDS complicated with heterogeneous multiple primary malignant tumors (MPMTs), and to provide clinical accumulation for the diagnosis and treatment of AIDS complicated with malignant tumor and improve prognosis.

Methods  The clinical features, treatment and prognosis of 6 cases of AIDS complicated with heterogeneous MPMTs were analyzed retrospectively.

Results  The first primary malignant tumor of the 6 AIDS patients was non-Hodgkin lymphoma (2 cases), skin cancer (2 cases), cervical cancer (1 case) and laryngeal cancer (1 case), respectively. The median age was 49(43, 58) years old, and the median CD4 cell count was 100 (55, 306) /μL. The second primary tumor was lung cancer (2 cases), colon cancer (2 cases), gastric cancer (1 case), and parotid gland malignancies (1  case), with an average CD4 cell count of (354±177) cells/μL. The mean interval between the two primary malignancies was (67±53) months, and three patients with gastrointestinal malignancies died at the end of follow-up, with a survival time of 3-9 months.

Conclusion  The AIDS patients with malignant tumors should be followed up regularly for a long time and be vigilant about the occurrence of MPMTs. Regular gastroenteroscopy can reduce the risk of malignant tumors of digestive tract and is expected to improve the  prognosis.

1.张智柏, 李浩, 李江, 等. 肝重复癌一例[J]. 肝胆胰外科杂志, 2025, 37(5): 350-352. [Zhang ZB, Li H, Li J, et al. A case of recurrent liver cancer[J]. Journal of Hepatopancreatobiliary Surgery, 2025, 37(5): 350-352.] DOI: 10.11952/j.issn.1007-1954. 2025.05.013.

2.Yang XB, Zhang LH, Xue JN, et al. High incidence combination of multiple primary malignant tumors of the digestive system[J]. World J Gastroenterol, 2022, 28(41): 5982-5992. DOI: 10.3748/wjg.v28.i41.5982.

3.Wang H, Hou J, Zhang G, et al. Clinical characteristics and prognostic analysis of multiple primary malignant neoplasms in patients with lung cancer[J]. Cancer Gene Ther, 2019, (26)11-12: 419-426. DOI: 10.1038/s41417-019-0084-z.

4.Zhu CL, Peng LZ. Clinical analysis of multiple primary gastrointestinal malignant tumors: a 10-year case review of a single-center[J]. World J Gastrointest Oncol, 2024, 16(4): 1204-1212. DOI: 10.4251/wjgo.v16.i4.1204.

5.Liu Z, Liu C, Guo W, et al. Clinical analysis of 152 cases of multiple primary malignant tumors in 15,398 patients with malignant tumors[J]. PLoS One, 2015, 10(5): e0125754. DOI: 10.1371/journal.pone.0125754.

6.Shmakova A, Germini D, Vassetzky Y. HIV-1, HAART and cancer: a complex relationship[J]. Int J Cancer, 2020, 146(10): 2666-2679. DOI: 10.1002/ijc.32730.

7.Copur MS, Manapuram S. Multiple primary tumors over a lifetime[J]. Oncology (Williston Park), 2019, 33(7): 629384. https://pubmed.ncbi.nlm.nih.gov/31365752/

8.Hessol NA, Whittemore H, Vittinghoff E, et al. Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study[J]. Lancet HIV, 2018, 5(11): e647-e655. DOI: 10.1016/S2352-3018(18)30179-6.

9.Allavena C, Fresard A, Brégigeon S, et al. Prevalence and spectrum of second primary malignancies among people living with HIV in the french Dat'AIDS cohort[J]. Cancers (Basel), 2022, 14(2): 401. DOI: 10.3390/cancers14020401.

10.Abrahão R, Brunson AM, Kahn JM, et al. Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors[J]. Leuk Lymphoma, 2022, 63(5): 1091-1101. DOI: 10.1080/10428194.2021.2020775.

11.陈双双, 马锐. 多原发癌的研究进展[J]. 癌症进展, 2019, 17(8): 883-886. [Chen SS, Ma R. Research progress of multiple primary cancers[J]. Cancer Progression, 2019, 17(8): 883-886.] DOI: 10.11877/j.issn.1672-1535.2019.17.08.04.

12.Zhai C, Cai Y, Lou F, et al. Multiple primary malignant tumors  - a clinical analysis of 15,321 patients with malignancies at a single center in China[J]. J Cancer, 2018, 9(16): 2795-2801. DOI: 10.7150/jca.25482.

13.Abigail KK, Laura M, Gillian OB, et al. Cervical cancer screening and treatment, HIV infection, and age: program implementation in seven regions of namibia[J]. PLoS One, 2022, 17(2): e0263920. DOI: org/10.1371/journal.pone.0263920.

14.Antonino C, Emanuela V, Annunziata G, et al. Hematologic cancers in individuals infected by HIV[J]. Blood, 2022, 139(7): 995-1012. DOI: 10.1182/blood.2020005469.

15.Rudolph JE, Calkins KL, Xu X, et al. Comparing cancer incidence in an observational cohort of medicaid beneficiaries with and without HIV, 2001-2015[J]. J Acquir Immune Defic Syndr, 2024, 95(1): 26-34. DOI: 10.1097/QAI.0000000000003318.

16.Ceccarelli M, Venanzi Rullo E, Marino MA, et al. Non-AIDS defining cancers: a comprehensive update on diagnosis and management[J]. Eur Rev Med Pharmacol Sci, 2020, 24(7): 3849-3875. DOI: 10.26355/eurrev-202004-20852.

17.Elizabeth YC, Anna C, Darya K, et al. The effect of non-AIDS-defining cancers on people living with HIV[J]. Lancet Oncol, 2021, 22(6): e240-e253. DOI: 10.1016/S1470-2045(21)00137-6.

18.Kelsey LC, Kevin CW, John AB, et al. Cancer disparities in people with human immunodeficiency virus: a systematic review of screening for non-AIDS-defining malignancies[J]. Cancer, 2019, 125(6): 843-853. DOI: 10.1002/cncr.31838.

19.Pietro R, Marina T, Janaki A, et al. Second primary cancers in people with HIV/AIDS: a national data linkage study of incidence and risk factors[J]. J Acquir Immune Defic Syndr, 2023, 93(1): 25-33. DOI: 10.1097/QAI.0000000000003172.

20.Poizot-Martin I, Lions C, Allavena C, et al. Determinants of second primary cancer type in survivors of virus-related and non-virus-related cancer living with HIV in the French Dat'AIDS cohort[J]. Cancer Control, 2021, 28: 10732748211066310. DOI: 10.1177/10732748211066310.

21.Wang HJ, Hou JJ, Zhang GW, et al. Clinical characteristics and prognostic analysis of multiple primary malignant neoplasms in patients with lung cancer[J]. Cancer Gene Ther, 2019, 26(11-12): 419-426. DOI: 10.1038/s41417-019-0084-z.

22.赫捷,李霓,陈万青,等. 中国肺癌筛查与早诊早治指南(2021,北京)[J]. 中国综合临床, 2021, 37(3): 193-207. [Hao J, Li N, Chen WQ, et al. Guidelines for screening and early diagnosis of lung cancer in China (2021, Beijing)[J]. Chinese General Clinic, 2021, 37(3): 193-207.] DOI: 10.3760/cma.j.cn112152-20210119-00060.

23.Xia CF, Li H, Xu YJ, et al. Effect of an endoscopy screening on upper gastrointestinal cancer mortality: a conmunity-based multicenter cluster randomized clinical trial[J]. Gastroenterology, 2025, 168(4): 725-740. DOI: 10.1053/j.gastro.2024.11.025.

24.Humberto KC, Peter JM. Lung cancer screening[J]. Surg Oncol Clin N Am, 2020, 29(4): 509-524. DOI: 10.1016/j.soc.2020.06.004.

25.Angelo ZM, Jose DD, Andre B, et al. Current impact of viral hepatitis on liver cancer development: the challenge remains[J]. World J Gastroenterol, 2021, 27(24): 3556-3567. DOI: 10.3748/wjg.v27.i24.3556.